These responses from the excess death inquiry matter because the witness has no vested interest in the vaccine, unlike the TGA who approved them.
••••••••••••••••••••••••••••••••••••
“The lack of pharmacokinetics and pharmacodynamic data which was available at the time of the rollout of these vaccines is very unique. It is very much the exception in the registration of pharmaceuticals. And it is acknowledged…….. that long term safety data wasn’t known.”
Committee on 13/06/2024
Community Affairs References Committee
Excess Mortality
Senator RENNICK: Do you think it was reckless for Pfizer to roll it out and for the TGA to approve it, given that there were no studies done on these important pathogenic risks?
Dr Neil: The lack of pharmacokinetic and pharmacodynamic data, which was available at the time of the rollout of these vaccines, is very unique. It’s very much the exception in registration of pharmaceuticals. It was acknowledged, perhaps because of those and other reasons, by the TGA at the time of the provisional registration that long-term safety data wasn’t known. I think it’s because of that they committed to ‘very rigorously’ look at safety signals. Our contention is that the safety signals were there, but there was no response. Yes, they collected the data, but there was no appropriate response, in our opinion.
